- Home
- AORT vs MDXG Comparison
AORT vs MDXG Comparison
Compare AORT & MDXG Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- AORT
- MDXG
- Stock Information
- Founded
- AORT 1984
- MDXG 2006
- Country
- AORT United States
- MDXG United States
- Employees
- AORT N/A
- MDXG N/A
- Industry
- AORT Medical/Dental Instruments
- MDXG Biotechnology: Pharmaceutical Preparations
- Sector
- AORT Health Care
- MDXG Health Care
- Exchange
- AORT Nasdaq
- MDXG Nasdaq
- Market Cap
- AORT 1.2B
- MDXG 1.1B
- IPO Year
- AORT 1993
- MDXG N/A
- Fundamental
- Price
- AORT $28.22
- MDXG $9.26
- Analyst Decision
- AORT Strong Buy
- MDXG Strong Buy
- Analyst Count
- AORT 5
- MDXG 5
- Target Price
- AORT $31.80
- MDXG $12.00
- AVG Volume (30 Days)
- AORT 236.3K
- MDXG 781.2K
- Earning Date
- AORT 02-13-2025
- MDXG 10-30-2024
- Dividend Yield
- AORT N/A
- MDXG N/A
- EPS Growth
- AORT N/A
- MDXG N/A
- EPS
- AORT N/A
- MDXG 0.52
- Revenue
- AORT $384,899,000.00
- MDXG $342,804,000.00
- Revenue This Year
- AORT $13.04
- MDXG $9.56
- Revenue Next Year
- AORT $9.66
- MDXG $9.19
- P/E Ratio
- AORT N/A
- MDXG $18.28
- Revenue Growth
- AORT 13.29
- MDXG 10.93
- 52 Week Low
- AORT $16.48
- MDXG $5.47
- 52 Week High
- AORT $30.45
- MDXG $10.14
- Technical
- Relative Strength Index (RSI)
- AORT 53.32
- MDXG 62.95
- Support Level
- AORT $28.52
- MDXG $9.07
- Resistance Level
- AORT $30.45
- MDXG $10.14
- Average True Range (ATR)
- AORT 0.72
- MDXG 0.31
- MACD
- AORT -0.13
- MDXG -0.11
- Stochastic Oscillator
- AORT 24.49
- MDXG 41.67
About AORT Artivion Inc.
Artivion Inc offers cardiac and vascular surgeons a suite of aortic-centric solutions. The company's products include Aortic Heart Valve, Mitral Heart Valve, Aortic Allograft, Pulmonary Human Heart Valve, Pulmonary Patch, and Surgical Adhesive among others.
About MDXG MiMedx Group Inc
MiMedx Group Inc develops and markets regenerative biomaterial products and bioimplants made from the human amniotic membrane, birth tissues, and human skin & bone. Its products are primarily targeted towards the wound-care, burn, surgical, sports medicine, and orthopedics markets. MiMedx's key products are allografts processed from amniotic tissue, which include EpiFix for external use and AmnioFix for internal use. AmnioCord, AmnioFill, EpiBurn, and EpiCord are some of its other products. Also, it sells allografts for ophthalmic surgery and dental applications through licenses to third parties.